The drug, Abilify MyCite, has an ingestible sensor embedded into the pill to record when the medication was taken. When the pill is swallowed, the sensor sends a message to a wearable patch, which then transmits information to a mobile app so patients can monitor their medication intake on their phones. Patients can also allow their caregivers and physicians to access the data from the app through an online portal.
Abilify MyCite, manufactured by Otsuka Pharmaceutical Co., is approved for schizophrenia, acute bipolar disorder and adult depression. The sensor technology and patch are made by Proteus Digital Health.
The FDA noted that the drug should not be used to track ingestion in real time, since detection may be delayed.
More articles on supply chain:
AHA urges FDA to address saline bag shortage
6 ways the proposed Republican tax overhaul could impact pharma
FDA Commissioner: Keep defense medical device approvals to us
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
